Supporting Information for

Alkylaluminium-Catalyzed Regioselective Hydrophosphinylation of

α, β -unsaturated Ketones into γ -Ketophosphine Oxides

Yiwen Chen,‡ Ziyuan Pang,‡ Gege Li, Xiaobo Yang, Wenliang Yan, Qifeng Li, Xuan Dong,

Xiaoli Ma* and Zhi Yang*

School of Chemistry and Chemical Engineering, Beijing Institute of Technology, 100081

Beijing, People's Republic of China

*Corresponding authors. E-mail addresses: maxiaoli@bit.edu.cn, zhiyang@bit.edu.cn

Contents

1. General considerations
2. Experimental Section
a) Preparation of a , β -unsaturated ketones3
b) Preparation of diarylphosphine oxides4
c) Synthesis of L1-L35
d) ¹ H and ¹³ C NMR data and spectra of L1-L35
e) Synthesis of C1-C69
f) ¹ H and ¹³ C NMR data and spectra of C1-C610
g) Single crystal X-ray structure and refinement18
h) Comparison of Catalytic Performance with Previously Reported Complexes
i) General Procedure for the Alkylaluminum-Catalyzed Hydrophosphinylation of a, β -
Unsaturated Ketones 22
j) Detailed Procedure for the Gram Synthesis of 3a and 3x
3. NMR data and spectra of γ -Ketophosphine Oxides
4. Substrate Scope Limitations and Observed Challenges
5. Control experiments for the mechanistic investigation97
6. References

1. General considerations

All air-sensitive reactions and product manipulations were conducted under a dry nitrogen atmosphere, utilizing standard Schlenk techniques or working in glove boxes with strict air and moisture exclusion. All solvents were refluxed over the appropriate drying agent and distilled prior to use. Commercially available chemicals were purchased from *J&K* chemical or Aldrich and used as received. TLC analysis was performed on silica gel plates coated with glass and visualized by UV lamp (254 nm). column chromatography was performed on silica gel (400-500 mesh). ¹H, ¹³C and ³¹P NMR spectra were recorded with a Bruker Avance III 400 MHz spectrometer. Melting points were measured in sealed glass tubes. CCDC-2426265-2426268 contain the supplementary crystallographic data for this paper. This data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/ data_request/cif.

2. Experimental Section

a) Preparation of α, β -unsaturated ketones

 α,β -unsaturated ketones **1** was synthesised following a reported procedure.¹ Using a similar approach. General procedure for of α,β -unsaturated ketones synthesis:



Scheme S2.1 Synthesis of α , β -unsaturated ketones

1-(triphenylphosphoranylidene)-2-ketone (40 mmol, 1.33 equivalents) was added to a solution of aldehyde (30 mmol, 1.0 equivalent) in toluene (50 mL) at room temperature. The reaction mixture was refluxed at 130 °C for 5 hours. Afterward, the mixture was extracted with EtOAc and H₂O. The combined organic layers were washed with brine, followed by water, and then dried over sodium sulfate. The resulting solution was concentrated under vacuum, and the residue was purified by column

chromatography using a mixture of petroleum ether and ethyl acetate (in a ratio ranging from 15:1 to 10:1, v/v).

b) Preparation of diarylphosphine oxides

diarylphosphine oxides was synthesised following a reported procedure.² Using a similar approach. General procedure for of diarylphosphine oxides synthesis:



Scheme S2.2 Synthesis of diarylphosphine oxides

Dissolving 10 mmol of diethylphosphite in 10 mL of THF, which was then added slowly dropwise to 35 mmol of aryl magnesium bromide while maintaining the mixture in an ice-water bath. The reaction was stirred at room temperature for 12 hours until completion. The reaction was quenched with saturated aqueous NH₄Cl in an ice-water bath and stirring was continued for 0.5 h at room temperature, then the mixture was extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine and subsequently dried over sodium sulfate. Final purification was achieved through column chromatography using a mixture of petroleum ether and ethyl acetate, with the ratio varying from 5:1 to 1:1 (v/v).

c) Synthesis of L1-L3



Scheme S2.3 Synthesis of L1-L3

Ligands **L1-L3** were synthesized using a similar approach. 2-acetylcyclohexanone (50 mmol) and aniline (100 mmol) were added to a solution of dry toluene (80 mL) and *p*-toluenesulfonic acid (2.5 mmol) was added as a catalyst. The mixture was heated under reflux conditions and the water formed was removed by azeotropy using a Dean-Stark apparatus for 72 h. Toluene was evaporated to give a brown solid. The crude product was washed by ice ethanol to white or yellow, and then recrystallized by ice ethyl acetate to obtain white or yellow solid.

d) ¹H and ¹³C NMR data and spectra of L1-L3

Ligand L1. 11.93 g, 52% yield; white solid; m.p. 164.4 – 166.7 °C. ¹H NMR (400 MHz, CDCl₃) δ 12.94 (s, 1H), 7.23 – 6.96 (m, 6H), 3.27 – 3.11 (m, 2H), 3.09 – 2.96 (m, 2H), 2.45 (t, *J* = 6.4 Hz, 2H), 1.98 (t, *J* = 6.3 Hz, 2H), 1.79 (s, 3H), 1.76 – 1.69 (m, 2H), 1.62 – 1.54 (m, 2H), 1.22 (d, *J* = 6.9 Hz, 6H), 1.16 (d, *J* = 6.9 Hz, 6H), 1.11 (t, *J* = 7.2 Hz, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 167.6, 155.2, 145.9, 145.0, 139.2, 136.7, 126.4,

123.1, 123.1, 122.9, 97.1, 77.4, 77.1, 76.7, 28.2, 28.1, 27.9, 26.8, 24.8, 23.9, 23.9, 23.6, 23.3, 22.1, 19.1.

Ligand L2. 13.25 g, 66% yield; light yellow solid; m.p. 160.3 – 162.7 °C. ¹H NMR (400 MHz, CDCl₃) δ 13.02 (s, 1H), 7.12 – 6.98 (m, 6H), 2.72 – 2.60 (m, 2H), 2.60 – 2.49 (m, 4H), 2.49 – 2.45 (m, 2H), 2.45 – 2.38 (m, 2H), 1.98 (t, *J* = 6.4 Hz, 2H), 1.78 (s, 3H), 1.76 – 1.68 (m, 2H), 1.64 – 1.54 (m, 2H), 1.20 – 1.15 (m, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 167.1, 155.1, 146.4, 141.3, 138.6, 134.5, 125.9, 125.9, 125.6, 122.8, 97.5, 28.0, 26.9, 24.6, 24.5, 24.2, 23.9, 22.3, 18.5, 14.7, 14.2, 13.9.

Ligand L3. 10.72 g, 57% yield; yellow solid; m.p. 167.2 – 170.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 12.96 (s, 1H), 6.85 (d, *J* = 10.2 Hz, 4H), 2.45 (t, *J* = 6.3 Hz, 2H), 2.27 (s, 6H), 2.16 (s, 6H), 2.06 (s, 6H), 1.97 (t, *J*=6.4 Hz, 2H), 1.77 (s, 3H), 1.74 – 1.68 (m, 2H), 1.63 – 1.57 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 166.9, 155.0, 145.1, 137.5, 135.2, 134.8, 131.5, 128.6, 128.4, 128.3, 97.5, 27.7, 26.9, 23.9, 22.4, 20.9, 20.7, 19.5, 18.5, 18.5, 17.9.



FigureS2.1 ¹H NMR spectrum of L1 (400 MHz, CDCl₃).



Figure S2.3 ¹H NMR spectrum of L2 (400 MHz, CDCl₃).



Figure S2.5 ¹H NMR spectrum of L3 (400 MHz, CDCl₃).



Figure S2.6 ¹³C NMR spectrum of L3 (101 MHz, CDCl₃).

e) Synthesis of C1-C6

Compounds C1–C6 were synthesised following a similar procedure. Under a nitrogen atmosphere, ligand L1–L3 (1.0 mmol) was dissolved in 10 mL of dry *n*-hexane in a flame-dried Schlenk flask and cooled to 0 °C using an ice bath. Subsequently, a 1.0 mL *n*-hexane solution of trimethylaluminium or triethylaluminium (1.0 mmol/mL, 1.0 mmol) was added dropwise over 5 minutes under continuous stirring. After the addition was complete, the reaction mixture was slowly warmed to room temperature and then heated to 50 °C, and stirred at this temperature for 12 hours. Upon completion of the reaction, the solvent was partially evaporated under reduced pressure to concentrate the solution to approximately 5 mL. The concentrated solution was then placed at –15 °C for 24 hours to allow crystallisation. The resulting yellow crystalline solids (C1–C6) were collected by filtration, washed with cold n-hexane, and dried under vacuum.



Scheme S2.4 Synthesis of C1-C6.

f) ¹H and ¹³C NMR data and spectra of C1-C6

Compound **C1**. 0.345 g, 64% yield; white solid; m.p. $181.1 - 184 \degree C. \degree H NMR$ (400 MHz, CDCl₃) δ 7.25 - 7.14 (m, 6H), 3.30 - 3.12 (m, 4H), 2.46 (t, *J* = 6.4 Hz, 2H), 2.06 (t, *J* = 6.6 Hz, 2H), 1.84 (s, 3H), 1.72 - 1.64 (m, 2H), 1.54 - 1.46 (m, 2H), 1.23 (t, *J* = 6.6 Hz, 12H), 1.15 - 1.08 (m, 12H), -1.05 (s, 6H). \degree ¹³C NMR (101 MHz, CDCl₃) δ 169.4, 167.7, 143.5, 143.1, 140.2, 140.1, 125.4, 124.8, 123.1, 123.0, 101.5, 30.9, 27.7, 27.0, 26.8, 24.4, 23.8, 23.6, 23.6, 22.1, 21.1, 20.5.

Compound **C2**. 0.266 g, 49% yield; light yellow solid; m.p. 173.4 – 176.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.25 – 7.15 (m, 6H), 3.33 – 3.21 (m, 4H), 2.42 (t, *J* = 6.3 Hz, 2H), 2.11 (t, *J* = 6.6 Hz, 2H), 1.85 (s, 3H), 1.69 – 1.61 (m, 2H), 1.55 – 1.46 (m, 2H), 1.28 (t, *J* = 6.9 Hz, 12H), 1.17 – 1.11 (m, 12H), 0.72 (t, *J* = 8.0 Hz, 6H), -0.29 – -0.44 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 170.6, 169.0, 144.3, 143.8, 141.1, 141.0, 126.2, 125.8, 123.9, 123.8, 103.0, 31.4, 28.3, 27.6, 27.4, 25.1, 24.6, 24.5, 24.3, 22.7, 21.8, 21.2, 9.2.

Compound **C3**. 0.389 g, 85% yield; yellow solid; m.p. 116.6 – 118.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.25 – 7.01 (m, 6H), 2.73 – 2.60 (m, 4H), 2.57 – 2.48 (m, 4H), 2.46 (t, *J* = 6.2 Hz, 2H), 2.04 (t, *J* = 6.6 Hz, 2H), 1.83 (s, 3H), 1.72 – 1.65 (m, 2H), 1.57 – 1.48 (m, 2H), 1.27 - 1.16 (m, 12H), -1.20 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 168.6, 166.8, 141.4, 141.3, 138.1, 138.0, 124.8, 124.6, 124.5, 100.2, 30.4, 28.7, 27.6, 22.9, 22.7, 22.2, 21.3, 18.9, 13.1, 13.1, -10.8.

Compound **C4**. 0.350 g, 72% yield; yellow solid; m.p. 79.2 – 83.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.19 – 7.07 (m, 6H), 2.77 – 2.63 (m, 4H), 2.61 – 2.51 (m, 4H), 2.44 (t, *J* = 6.3 Hz, 2H), 2.07 (t, *J* = 6.6 Hz, 2H), 1.84 (s, 3H), 1.70 – 1.63 (m, 2H), 1.57 – 1.50 (m, 2H), 1.26 – 1.19 (m, 12H), 0.59 (t, *J* = 8.0 Hz, 6H), -0.45 – -0.56 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 169.8, 168.2, 142.7, 142.7, 139.2, 139.0, 125.8, 125.6, 125.5, 102.5, 31.2,

28.6, 23.8, 23.6, 23.2, 22.3, 19.8, 14.2, 14.1, 9.1.

Compound **C5**. 0.381 g, 88% yield; yellow solid; m.p. 136.9 – 139.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.88 (d, *J* = 4.8 Hz, 4H), 2.45 (t, *J* = 6.3 Hz, 2H), 2.27 (d, *J* = 2.4 Hz, 6H), 2.14 (d, *J* = 2.7 Hz, 12H), 2.01 (t, *J* = 6.6 Hz, 2H), 1.79 (s, 3H), 1.69 – 1.63 (m, 2H), 1.57 – 1.50 (m, 2H), -1.15(s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 168.4, 166.5, 140.0, 139.8, 133.7, 133.4, 132.5, 132.4, 128.1, 128.1, 99.8, 30.1, 27.7, 22.3, 21.5, 19.8, 19.8, 18.0, 17.8, -10.0.

Compound **C6**. 0.243 g, 53% yield; yellow solid; m.p. 81.7 – 84.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 6.87 (d, *J* = 5.7 Hz, 4H), 2.43 (t, *J* = 6.2 Hz, 2H), 2.26 (d, *J* = 2.5 Hz, 6H), 2.18 (d, *J* = 4.4 Hz, 12H), 2.04 (t, *J* = 6.6 Hz, 2H), 1.80 (s, 3H), 1.68 – 1.61 (m, 2H), 1.57 – 1.50 (m, 2H), 0.62 (t, *J* = 8.0 Hz, 6H), -0.36 – -0.52 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 168.5, 166.7, 140.3, 140.2, 133.6, 133.4, 132.4, 132.3, 128.1, 128.1, 101.1, 29.9, 27.7, 22.2, 21.5, 19.8, 17.9, 17.7, 8.0.



Figure S2.8¹³C NMR spectrum of C1 (101 MHz, CDCl₃).



Figure S2.10¹³C NMR spectrum of C2 (101 MHz, CDCl₃).



Figure S2.12 ¹³C NMR spectrum of C3 (101 MHz, CDCl₃).



Figure S2.14 ¹³C NMR spectrum of C4 (101 MHz, CDCl₃).



Figure S2.16¹³C NMR spectrum of C5 (101 MHz, CDCl₃).



Figure S2.18 $^{\rm 13}{\rm C}$ NMR spectrum of C6 (101 MHz, CDCl₃).

g) Single crystal X-ray structure and refinement

The single-crystal structures of **C2**, **C3**, and **C5** were successfully obtained from the *n*-hexane mother liquor. Additionally, the single-crystal structure of the catalytic product **3w** was obtained from ethyl acetate. The crystal data were collected on a Rigaku Oxford diffractometer. Selected data collection parameters and other crystallographic results are summarized in **Table S2.1** and **Table S2.2**. Structure solution by direct methods was achieved through the use of the SHELXT program, and the structural model refined by full matrix least-squares on F^2 using SHELXL by using the Olex2 software.³⁻⁵ All non-hydrogen atoms were refined anisotropically. Hydrogen atom positions were calculated geometrically and refined using the riding model. The molecular structures of **C2**, **C3** and **3w** are shown in Figures **S2.19–S2.21**.



Figure S2.19 Molecular structure of **C2**. Thermal ellipsoids are drawn at the 50% level and the hydrogen atoms are omitted for clarity.



Figure S2.20 Molecular structure of **C3**. Thermal ellipsoids are drawn at the 50% level and the hydrogen atoms are omitted for clarity.

Identification code	C2	С3	C5	
CCDC	2426265	2426266	2426267	
Empirical formula	$C_{36}H_{55}AIN_2$	$C_{30}H_{43}AIN_2$	$C_{28}H_{39}AIN_2$	
Formula weight	542.8	458.64	430.59	
Temperature/K	293(2)	99.99(10)	99.9(2)	
Crystal system	monoclinic	orthorhombic	orthorhombic	
Space group	P2 ₁ /n	Aem2	P212121	
a/Å	10.4055(4)	15.6163(7)	16.5787(4)	
b/Å	25.6624(12)	22.5091(9)	20.7155(4)	
c/Å	12.8303(6)	7.7370(5)	29.8150(6)	
α/°	90	90	90	
β/°	103.621(4)	90	90	
γ/°	90	90	90	
Volume/ų	3329.7(3)	2719.6(2)	10239.5(4)	
Z	4	4	16	
$\rho_{calc}g/cm^3$	1.083	1.12	1.117	
µ/mm⁻¹	0.086	0.094	0.096	
F(000)	1192	1000	3744	
Crystal size/mm ³	$0.34 \times 0.21 \times 0.15$	0.13 imes 0.12 imes 0.1	$0.15 \times 0.12 \times 0.1$	
Radiation	ΜοΚα (λ =	Μο Κα (λ =	Μο Κα (λ =	
20	0.71073)	0.71073)	0.71073)	
20 range for data collection/°	6.572 to 61.97	7.242 to 62.162	3.932 to 61.676	
Index ranges	-14 ≤ h ≤ 11, -35 ≤	-19 ≤ h ≤ 21, -31 ≤	-22 ≤ h ≤ 19, -27 ≤	
	$k \le 37, -15 \le \le 18$	$k \le 28, -10 \le \le 9$	$k \le 26, -35 \le 1 \le 42$	
Reflections collected	23020	8882	66871	
Indonondont roflastics	$8301 [R_{int} = 0.0917 R_{1000} = -$	$32/9 [R_{int} = 0.0436 R_{conv} = -0.0436 R_{conv} = -0.0438 R_{conv$	$24858 [R_{int} = 0.0424 R_{cons} = -$	
independent reflections	0.1008]	0.0350]	0.0424, Rsigma – 0.0621]	
Data/restraints/parameters	8301/41/393	3279/20/182	24858/0/1153	
Goodness-of-fit on F ²	1.102	1.079	1.04	
	R ₁ = 0.0797, wR ₂ =	R ₁ = 0.0636,	R ₁ = 0.0461,	
Final R indexes [I>=20 (I)]	0.2132	wR ₂ = 0.1627	wR ₂ = 0.1108	
Final R indexes [all data]	$R_1 = 0.1147, wR_2 =$	$R_1 = 0.0670,$	$R_1 = 0.0692,$	
	0.2340	$wR_2 = 0.1645$	$wR_2 = 0.1184$	
Largest diff. peak/hole / e Å ⁻³	0.84/-0.62	0.36/-0.24	0.48/-0.23	

 Table S2.1 Crystal data and structure refinement for C2, C3 and C5.

Identification code	3w		
CCDC	2426268		
Empirical formula	C ₂₅ H ₂₇ O ₂ P		
Formula weight	390.43		
Temperature/K	293(2)		
Crystal system	monoclinic		
Space group	P21		
a/Å	5.7275(3)		
b/Å	20.7047(12)		
c/Å	17.3578(11)		
α/°	90		
β/°	91.347(6)		
γ/°	90		
Volume/Å ³	2057.8(2)		
Z	2		
$\rho_{calc}g/cm^3$	1.26		
µ/mm⁻¹	0.151		
F(000)	832		
Crystal size/mm ³	0.33 × 0.27 × 0.16		
Radiation	ΜοΚα (λ = 0.71073)		
20 range for data collection/°	7.044 to 51.358		
Index ranges	-6 ≤ h ≤ 6, -25 ≤ k ≤ 25, -18 ≤ l ≤ 21		
Reflections collected	12550		
Independent reflections	7069 [R _{int} = 0.0483, R _{sigma} = 0.0718]		
Data/restraints/parameters	7069/1875/984		
Goodness-of-fit on F ²	1.107		
Final R indexes [I>=2σ (I)]	$[I>=2\sigma(I)]$ R ₁ = 0.1083, wR ₂ = 0.2806		
Final R indexes [all data]	R ₁ = 0.1171, wR ₂ = 0.2867		
Largest diff. peak/hole / e Å ⁻³	1.31/-0.72		

Table S2.2 Crystal data and structure refinement for 3w.



Figure S2.21 Molecular structure of **3w**. Thermal ellipsoids are drawn at the 50% level and the hydrogen atoms are omitted for clarity.

h) Comparison of Catalytic Performance with Previously Reported Complexes

Based on the optimisation studies presented in Table 1 of the main text, the optimal reaction conditions were identified as employing catalyst **C5** in toluene at 80 °C for 3 hours. Under these conditions, we further evaluated the catalytic performance of several related aluminium complexes previously synthesised by our group (**Fig. S2.22**), in order to compare their activities with that of **C5**. Unless otherwise specified, reactions were conducted under nitrogen atmosphere using **1a** (1 mmol), **2a** (1.2 equiv., 1.2 mmol), with stirring at the indicated temperature. The corresponding yields of the isolated products are summarised in **Table S2.3**.



Figure S2.22 Comparative catalytic efficiencies of aluminium complexes in the hydrophosphinylation of α , β -unsaturated ketones

Ph	+	O H-P-Ph Ph	Conditions		D Ph U O H P P Ph
1a		2a			3a
entry	Cat. (mol%)	solvent	T (°C)	t (h)	yield (%) ^b
1	C5 (5)	Tol	80	3	96
2	Cat A	Tol	80	3	95
3	Cat B	Tol	80	3	81
4	Cat C	Tol	80	3	79
5	Cat D	Tol	80	3	83
6	Cat E	Tol	80	3	89

 Table S2.3 Comparative catalytic efficiencies of aluminium complexes.^a

^a Experimental conditions: 1a (1 mmol), 2a (1.2 equiv., 1.2 mmol), catalyst (mol%), and solvent (2.5 mL) stirred at the indicated temperature under nitrogen. ^b Isolated yields.

i) General Procedure for the Alkylaluminium-Catalyzed Hydrophosphinylation of α, β -Unsaturated Ketones



Scheme S2.5 Synthesis of 3

Under a nitrogen atmosphere, all operations were carried out either in a glovebox or using standard Schlenk techniques. α , β -Unsaturated ketone (1.0 mmol) and diarylphosphine oxide (1.2 mmol) were sequentially added to a flame-dried 10 mL Schlenk flask equipped with a magnetic stir bar. Subsequently, the catalyst (5 mol%) was added as a solid. Finally, distilled toluene (2.5 mL) was introduced via syringe under nitrogen protection. The reaction mixture was stirred and heated in an oil bath at 80 °C for 3 hours. Upon completion, the reaction mixture was allowed to cool to room temperature. The solvent was then removed under reduced pressure to afford a yellow crude product. The crude product was purified by flash column chromatography on silica gel using a mixture of dichloromethane and methanol (30:1, v/v) as the eluent, affording the desired product as a white or pale yellow powder.

j) Detailed Procedure for the Gram Synthesis of 3a and 3x

Under the atmosphere of nitrogen, 10 mmol **1a** (1.462 g) or **1x** (2.083 g) and 12 mmol (2.424 g) of **2a** were added to a 100 mL Schlenk reaction flask, followed by 1 mmol% **C5** (0.043 g), and finally 25 mL of redistilled toluene. The resulting solution was reacted under an oil bath at 80 °C for 24 h. After the solution was cooled, the solvent was drained to give a white crude product. The crude product was separated by column chromatography, dichloromethane: methanol=30:1, to obtain a white powder. **3a** was obtained with 2.96 g in 85% yield as white solid, **3x** was obtained with 3.56 g in 87% yield as white solid.

3. NMR data and spectra of y-Ketophosphine Oxides

4-(Diphenylphosphoryl)-4-phenylbutan-2-one (**3a**). 96% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.97 – 7.87 (m, 2H), 7.61 – 7.48 (m, 3H), 7.48 – 7.37 (m, 2H), 7.36 – 7.26 (m, 3H), 7.26 – 7.20 (m, 2H), 7.19 – 7.09 (m, 3H), 4.22 (ddd, *J* = 10.2, 7.3, 2.9 Hz, 1H), 3.33 (ddd, *J* = 17.9, 10.1, 5.3 Hz, 1H), 2.94 (ddd, *J* = 18.0, 11.2, 2.9 Hz, 1H), 1.95 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.4 (d, *J*_{C-P} = 12.6 Hz), 135.9 (d, *J*_{C-P} = 5.7 Hz), 132.0 (d, *J*_{C-P} = 2.9 Hz), 131.9, 131.4 (d, *J*_{C-P} = 2.9 Hz), 131.3 (d, *J*_{C-P} = 8.5 Hz), 131.0 (d, *J*_{C-P} = 2.9 Hz), 131.0 (d, *J*_{C-P} = 11.8 Hz), 127.1 (d, *J*_{C-P} = 2.5 Hz), 43.6, 41.1 (d, *J*_{C-P} = 68.9 Hz), 30.6. ³¹P NMR (162 MHz, CDCl₃) δ 33.60.

4-(Diphenylphosphoryl)-4-(2-tolyl)butan-2-one (3b). 98% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.00 – 7.90 (m, 2H), 7.68 (d, *J* = 7.9 Hz, 1H), 7.63 – 7.52 (m, 3H), 7.32 (d, *J* = 1.6 Hz, 1H), 7.24 – 7.11 (m, 5H), 7.10 – 7.03 (m, 1H), 6.89 (d, *J* = 7.5 Hz, 1H), 4.35 (ddd, *J* = 10.3, 7.5, 2.8 Hz, 1H), 3.30 (ddd, *J* = 18.0, 10.1, 5.1 Hz, 1H), 2.88 (ddd, *J* = 18.1, 11.1, 2.8 Hz, 1H), 1.98 (s, 3H), 1.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.5 (d, *J*_{C-P} = 13.1 Hz), 137.3 (d, *J*_{C-P} = 6.4 Hz), 134.3 (d, *J*_{C-P} = 5.7 Hz), 132.3, 132.2 (d, *J*_{C-P} = 2.7 Hz), 131.7 (d, *J*_{C-P} = 8.3 Hz), 131.5 (d, *J*_{C-P} = 2.8 Hz), 131.2 (d, *J*_{C-P} = 23.5 Hz), 130.9 (d, *J*_{C-P} = 9.3 Hz), 130.1 (d, *J*_{C-P} = 2.1 Hz), 129.0 (d, *J*_{C-P} = 11.2 Hz), 128.8, 127.8 (d, *J*_{C-P} = 11.7 Hz), 127.1 (d, *J*_{C-P} = 2.7 Hz), 126.3 (d, *J*_{C-P} = 2.4 Hz), 44.4, 36.1 (d, *J*_{C-P} = 68.7 Hz), 30.5, 19.6. ³¹P NMR (162 MHz, CDCl₃) δ 34.14.

4-(Diphenylphosphoryl)-4-(3-tolyl)butan-2-one (**3c**). 97% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.95 – 7.86 (m, 2H), 7.57 – 7.49 (m, 3H), 7.45 – 7.38 (m, 2H), 7.34 – 7.29 (m, 1H), 7.25 – 7.19 (m, 2H), 7.09 – 7.00 (m, 3H), 6.95 – 6.88 (m, 1H), 4.11 (ddd, J = 10.3, 7.5, 2.9 Hz, 1H), 3.24 (ddd, J = 17.9, 10.1, 5.4 Hz, 1H), 2.86 (ddd, J = 18.0, 11.3, 3.0 Hz, 1H), 2.97 – 2.87 (m, 1H), 2.19 (s, 3H), 1.94 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.5 (d, $J_{C-P} = 12.7$ Hz), 137.9 (d, $J_{C-P} = 2.1$ Hz), 135.6 (d, $J_{C-P} = 5.5$ Hz), 132.0 (d, $J_{C-P} = 2.8$ Hz), 131.9 (d, $J_{C-P} = 5.4$ Hz), 131.4, 131.3 (d, $J_{C-P} = 8.6$ Hz), 131.1 (d, $J_{C-P} = 8.8$ Hz), 131.0, 130.5 (d, $J_{C-P} = 5.6$ Hz), 128.9 (d, $J_{C-P} = 11.2$ Hz), 128.2 (d, $J_{C-P} = 2.0$ Hz), 128.0 (d,

 J_{C-P} = 11.8 Hz), 127.9 (d, J_{C-P} = 2.6 Hz), 126.8 (d, J_{C-P} = 5.8 Hz), 43.5, 41.0 (d, J_{C-P} = 68.6 Hz), 30.7, 21.3. ³¹P NMR (162 MHz, CDCl₃) δ 33.53.

4-(Diphenylphosphoryl)-4-(4-tolyl)butan-2-one (**3d**). 91% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.01 – 7.80 (m, 2H), 7.62 – 7.38 (m, 5H), 7.36 – 7.28 (m, 1H), 7.26 – 7.20 (m, 2H), 7.20 – 7.11 (m, 2H), 6.96 (d, *J* = 7.8 Hz, 2H), 4.12 (ddd, *J* = 10.2, 7.4, 2.9 Hz, 1H), 3.21 (ddd, *J* = 17.8, 10.2, 5.4 Hz, 1H), 2.84 (ddd, *J* = 17.9, 11.1, 2.9 Hz, 1H), 2.22 (s, 3H), 1.93 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.5 (d, *J*_{C-P} = 12.9 Hz), 136.7 (d, *J*_{C-P} = 2.6 Hz), 132.7 (d, *J*_{C-P} = 5.6 Hz), 132.1 (d, *J*_{C-P} = 2.1 Hz), 131.9 (d, *J*_{C-P} = 2.7 Hz), 131.4 (d, *J*_{C-P} = 2.7 Hz), 131.3 (d, *J*_{C-P} = 8.5 Hz), 131.2 (d, *J*_{C-P} = 7.9 Hz), 131.0 (d, *J*_{C-P} = 8.8 Hz), 129.6 (d, *J*_{C-P} = 5.7 Hz), 129.1 (d, *J*_{C-P} = 1.9 Hz), 128.8 (d, *J*_{C-P} = 11.3 Hz), 128.1 (d, *J*_{C-P} = 11.8 Hz), 43.6, 40.7 (d, *J*_{C-P} = 69.1 Hz), 30.7, 21.0. ³¹P NMR (162 MHz, CDCl₃) δ 33.40.

4-(Diphenylphosphoryl)-4-(4-Chlorophenyl)butan-2-one (**3e**). 97% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.96 – 7.87 (m, 2H), 7.60 – 7.49 (m, 3H), 7.50 – 7.42 (m, 2H), 7.39 – 7.32 (m, 1H), 7.31 – 7.26 (m, 2H), 7.26 – 7.21 (m, 2H), 7.13 (d, *J* = 8.5 Hz, 2H), 4.20 (ddd, *J* = 10.1, 7.2, 2.9 Hz, 1H), 3.27 (ddd, *J* = 18.1, 10.2, 5.1 Hz, 1H), 2.92 (ddd, *J* = 18.1, 11.0, 2.9 Hz, 1H), 1.96 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.0 (d, *J*_C– P = 12.7 Hz), 134.6 (d, *J*_C–P = 5.5 Hz), 133.0 (d, *J*_C–P = 2.9 Hz), 132.1 (d, *J*_C–P = 2.8 Hz), 131.8, 131.6 (d, *J*_C–P = 3.0 Hz), 131.2 (d, *J*_C–P = 8.6 Hz), 131.0 (d, *J*_C–P = 5.8 Hz), 130.9 (d, *J*_C–P = 8.8 Hz), 130.7 (d, *J*_C–P = 4.7 Hz), 130.0 (d, *J*_C–P = 11.3 Hz), 128.5 (d, *J*_C–P = 2.1 Hz), 128.3 (d, *J*_C–P = 11.8 Hz), 43.6, 40.4 (d, *J*_C–P = 68.6 Hz), 30.6. ³¹P NMR (162 MHz, CDCl₃) δ 33.15.

4-(Diphenylphosphoryl)-4-(4-fluorophenyl)butan-2-one (**3f**). 92% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (ddd, *J* = 10.8, 7.9, 1.6 Hz, 2H), 7.52 – 7.43 (m, 3H), 7.41 – 7.34 (m, 2H), 7.27 (d, *J* = 6.0 Hz, 1H), 7.23 – 7.20 (m, 2H), 7.18 (dd, *J* = 3.1, 1.3 Hz, 2H), 6.84 – 6.73 (m, 2H), 4.13 (ddd, *J* = 10.1, 7.1, 2.9 Hz, 1H), 3.20 (ddd, *J* = 18.0, 10.3, 5.1 Hz, 1H), 2.84 (ddd, *J* = 18.1, 10.9, 2.9 Hz, 1H), 1.89 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.2 (d, *J*_{C-P} = 12.8 Hz), 161.9 (dd, *J*_{C-F} = 246.1, 2.6 Hz), 132.1 (d, *J*_{C-P} = 2.9 Hz), 131.9, 131.7 (s), 131.6 (d, *J*_{C-P} = 2.8 Hz), 131.2 (d, *J*_{C-P} = 8.5 Hz), 131.2 (d, *J*_{C-P} = 13.4 Hz), 130.9 (d, *J*_{C-P} = 8.8 Hz), 129.0 (d, *J*_{C-P} = 11.3 Hz), 128.2 (d, *J*_{C-P} = 11.8 Hz), 115.4 (d, *J*_{C-P} = 1.9 Hz), 115.2 (d, J_{C-P} = 2.0 Hz), 43.7, 40.2 (d, J_{C-P} = 69.1 Hz), 30.6. ³¹P NMR (162 MHz, CDCl₃) δ 33.38. ¹⁹F NMR (376 MHz, CDCl₃) δ -115.20.

4-(Diphenylphosphoryl)-4-(4-bromophenyl)butan-2-one (3g). 88% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (ddt, *J* = 10.9, 6.6, 1.6 Hz, 2H), 7.56 – 7.34 (m, 5H), 7.33 – 7.26 (m, 1H), 7.24 – 7.20 (m, 3H), 7.18 (dd, *J* = 3.0, 1.2 Hz, 1H), 7.12 (dd, *J* = 8.5, 1.9 Hz, 2H), 4.11 (ddd, *J* = 10.1, 7.1, 2.8 Hz, 1H), 3.19 (ddd, *J* = 18.1, 10.2, 5.1 Hz, 1H), 2.84 (ddd, *J* = 18.1, 11.0, 2.8 Hz, 1H), 1.89 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.0 (d, *J*_{C-P} = 12.7 Hz), 135.1 (d, *J*_{C-P} = 5.6 Hz), 132.2 (d, *J*_{C-P} = 2.8 Hz), 131.8, 131.7 (d, *J*_{C-P} = 2.5 Hz), 131.5 (d, *J*_{C-P} = 1.9 Hz), 131.4 (d, *J*_{C-P} = 5.7 Hz), 131.2 (d, *J*_{C-P} = 8.5 Hz), 130.9 (d, *J*_{C-P} = 8.9 Hz), 130.7 (d, *J*_{C-P} = 3.9 Hz), 129.0 (d, *J*_{C-P} = 11.4 Hz), 128.3 (d, *J*_{C-P} = 11.8 Hz), 121.3 (d, *J*_{C-P} = 3.2 Hz), 43.6, 40.5 (d, *J*_{C-P} = 68.4 Hz), 30.6. ³¹P NMR (162 MHz, CDCl₃) δ 32.96.

4-(Diphenylphosphoryl)-4-(4-hydroxyphenyl)butan-2-one (3h). 98% yield, white solid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.19 (s, 1H), 8.07 – 7.89 (m, 2H), 7.73 – 7.64 (m, 2H), 7.60 – 7.51 (m, 3H), 7.42 – 7.28 (m, 3H), 7.16 – 7.05 (m, 2H), 6.57 – 6.47 (m, 2H), 4.35 (ddd, *J* = 10.9, 7.5, 3.1 Hz, 1H), 3.13 (ddd, *J* = 16.9, 11.3, 5.9 Hz, 1H), 2.60 (ddd, *J* = 16.7, 9.4, 3.0 Hz, 1H), 1.90 (s, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 210.8 (d, *J*_{C-P} = 14.3 Hz), 161.2 (d, *J*_{C-P} = 2.2 Hz), 138.3 (d, *J*_{C-P} = 43.0 Hz), 137.3 (d, *J*_{C-P} = 49.8 Hz), 136.9 (d, *J*_{C-P} = 2.7 Hz), 136.4 (d, *J*_{C-P} = 2.7 Hz), 136.0 (d, *J*_{C-P} = 4.6 Hz), 135.9 (d, *J*_{C-P} = 4.5 Hz), 135.8 (d, *J*_{C-P} = 5.6 Hz), 134.0 (d, *J*_{C-P} = 11.0 Hz), 133.3 (d, *J*_{C-P} = 11.4 Hz), 131.1 (d, *J*_{C-P} = 5.9 Hz), 120.0 (d, *J*_{C-P} = 1.9 Hz), 48.0, 44.3 (d, *J*_{C-P} = 69.0 Hz), 35.4. ³¹P NMR (162 MHz, DMSO-*d*₆) δ 31.67.

4-(Diphenylphosphoryl)-4-(4-methoxyphenyl)butan-2-one (3i). 95% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (ddt, J = 9.7, 6.4, 1.7 Hz, 2H), 7.51 – 7.35 (m, 5H), 7.30 – 7.24 (m, 1H), 7.19 – 7.10 (m, 4H), 6.69 – 6.58 (m, 2H), 4.09 (ddd, J = 10.3, 7.4, 2.9 Hz, 1H), 3.64 (s, 3H), 3.20 (ddd, J = 17.8, 10.3, 5.3 Hz, 1H), 2.82 (ddd, J = 17.9, 10.8, 2.9 Hz, 1H), 1.87 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.5 (d, J_{C-P} = 13.0 Hz), 157.6 (d, J_{C-P} = 2.2 Hz), 131.1 (d, J_{C-P} = 7.5 Hz), 130.9 (d, J_{C-P} = 2.8 Hz), 130.4 (d, J_{C-P} = 2.9 Hz), 130.3 (d, J_{C-P} = 8.5 Hz), 130.1, 130.0 (d, J_{C-P} = 8.8 Hz), 129.7 (d, J_{C-P} = 5.6 Hz),

127.8 (d, $J_{C-P} = 11.3$ Hz), 127.1 (d, $J_{C-P} = 11.7$ Hz), 126.6 (d, $J_{C-P} = 5.6$ Hz), 112.8 (d, $J_{C-P} = 1.9$ Hz), 54.1, 42.7, 39.2 (d, $J_{C-P} = 69.5$ Hz), 29.7. ³¹P NMR (162 MHz, CDCl₃) δ 33.57. **4-(4-(Dimethylamino)phenyl)-4-(diphenylphosphoryl)butan-2-one (3j).** 77% yield, yellow solid; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (ddd, J = 10.2, 7.6, 1.8 Hz, 2H), 7.47 – 7.36 (m, 5H), 7.29 – 7.23 (m, 1H), 7.17 (dd, J = 7.5, 2.8 Hz, 2H), 7.09 – 7.03 (m, 2H), 6.56 – 6.41 (m, 2H), 4.06 (ddd, J = 10.4, 7.6, 2.9 Hz, 1H), 3.18 (ddd, J = 17.5, 10.3, 5.5 Hz, 1H), 2.88 – 2.80 (m, 1H), 2.78 (s, 6H), 1.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.8 (d, $J_{C-P} = 13.1$ Hz), 149.6 (d, $J_{C-P} = 1.9$ Hz), 132.4 (d, $J_{C-P} = 3.4$ Hz), 131.8 (d, $J_{C-P} = 2.8$ Hz), 131.5 (d, $J_{C-P} = 10.6$ Hz), 131.4 (d, $J_{C-P} = 8.5$ Hz), 131.3, 131.2 (d, $J_{C-P} = 8.8$ Hz), 130.4 (d, $J_{C-P} = 1.8$ Hz), 128.8 (d, $J_{C-P} = 11.1$ Hz), 128.0 (d, $J_{C-P} = 11.6$ Hz), 123.0 (d, $J_{C-P} = 5.7$ Hz), 112.5 (d, $J_{C-P} = 1.8$ Hz), 43.7, 40.5, 40.2 (d, $J_{C-P} = 69.9$ Hz), 30.7. ³¹P NMR (162 MHz, CDCl₃) δ 33.63.

4-(Diphenylphosphoryl)-4-(4-nitrophenyl)butan-2-one (3k). 98% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.99 – 7.91 (m, 2H), 7.87 (ddt, *J* = 11.0, 6.5, 1.6 Hz, 2H), 7.50 (dddd, *J* = 12.4, 6.6, 4.6, 3.3 Hz, 3H), 7.45 – 7.37 (m, 4H), 7.33 – 7.27 (m, 1H), 7.25 – 7.20 (m, 2H), 4.27 (ddd, *J* = 10.0, 7.0, 2.8 Hz, 1H), 3.27 (ddd, *J* = 18.5, 10.3, 5.0 Hz, 1H), 2.92 (ddd, *J* = 18.5, 10.9, 2.8 Hz, 1H), 1.91 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.5 (d, *J*_{C-P} = 12.3 Hz), 146.9 (d, *J*_{C-P} = 2.9 Hz), 144.1 (d, *J*_{C-P} = 5.4 Hz), 132.4 (d, *J*_{C-P} = 2.7 Hz), 132.0 (d, *J*_{C-P} = 2.8 Hz), 131.3, 131.2 (d, *J*_{C-P} = 8.6 Hz), 130.7 (d, *J*_{C-P} = 9.0 Hz), 130.6 (d, *J*_{C-P} = 5.5 Hz), 130.2 (d, *J*_{C-P} = 16.3 Hz), 129.1 (d, *J*_{C-P} = 11.4 Hz), 128.5 (d, *J*_{C-P} = 11.9 Hz), 123.4 (d, *J*_{C-P} = 1.9 Hz), 43.5, 41.2 (d, *J*_{C-P} = 66.6 Hz), 30.4. ³¹P NMR (162 MHz, CDCl₃) δ 32.54.

4-(Diphenylphosphoryl)-4-(4-(trifluoromethyl)phenyl)butan-2-one (3l). 97% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (ddt, *J* = 11.0, 6.5, 1.7 Hz, 2H), 7.53 – 7.44 (m, 3H), 7.43 – 7.31 (m, 6H), 7.30 – 7.25 (m, 1H), 7.20 – 7.14 (m, 2H), 4.22 (ddd, *J* = 10.1, 7.1, 2.9 Hz, 1H), 3.25 (ddd, *J* = 18.3, 10.2, 5.1 Hz, 1H), 2.89 (ddd, *J* = 18.3, 11.1, 2.9 Hz, 1H), 1.89 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.8 (d, *J*_{C-P} = 12.5 Hz), 140.4 (d, *J*_{C-P} = 5.3 Hz), 132.3 (d, *J*_{C-P} = 2.8 Hz), 131.7 (d, *J*_{C-P} = 2.9 Hz), 131.5 (d, *J*_{C-P} = 13.9 Hz), 131.2 (d, *J*_{C-P} = 8.5 Hz), 130.8 (d, *J*_{C-P} = 8.9 Hz), 130.5 (d, *J*_{C-P} = 9.1 Hz), 130.0 (d, *J*_{C-P} = 5.6 Hz), 129.4, 129.0 (d, *J*_{C-P} = 11.5 Hz), 128.3 (d, *J*_{C-P} = 11.8 Hz), 125.2, 124.0 (d, *J*_{C-P} =

272.1 Hz), 43.5, 41.0 (d, J_{C-P} = 67.8 Hz), 30.4. ³¹P NMR (162 MHz, CDCl₃) δ 33.03. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.61.

4-(1-(Diphenylphosphoryl)-3-oxobutyl)benzonitrile (3m). 96% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (ddt, *J* = 10.8, 8.0, 1.2 Hz, 2H), 7.53 – 7.44 (m, 3H), 7.42 – 7.34 (m, 6H), 7.32 – 7.26 (m, 1H), 7.21 – 7.14 (m, 2H), 4.23 – 4.16 (m, 1H), 3.24 (ddd, *J* = 18.5, 10.2, 5.1 Hz, 1H), 2.90 (ddd, *J* = 18.5, 11.0, 2.8 Hz, 1H), 1.90 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.6 (d, *J*_{C-P} = 12.4 Hz), 141.9 (d, *J*_{C-P} = 5.5 Hz), 132.4 (d, *J*_{C-P} = 2.6 Hz), 132.0 (d, *J*_{C-P} = 1.9 Hz), 131.9 (d, *J*_{C-P} = 2.8 Hz), 131.4, 131.2 (d, *J*_{C-P} = 8.5 Hz), 130.7 (d, *J*_{C-P} = 8.9 Hz), 130.5 (d, *J*_{C-P} = 5.5 Hz), 130.3 (d, *J*_{C-P} = 21.1 Hz), 129.1 (d, *J*_{C-P} = 11.5 Hz), 128.4 (d, *J*_{C-P} = 12.0 Hz), 118.6 (d, *J*_{C-P} = 1.6 Hz), 111.0 (d, *J*_{C-P} = 2.6 Hz), 43.4, 41.3 (d, *J*_{C-P} = 66.8 Hz), 30.4. ³¹P NMR (162 MHz, CDCl₃) δ 32.73.

4-(Diphenylphosphoryl)-4-(naphthalen-2-yl)butan-2-one (3n). 87% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.94 – 7.84 (m, 2H), 7.71 (t, *J* = 2.1 Hz, 1H), 7.67 – 7.61 (m, 2H), 7.57 (d, *J* = 8.5 Hz, 1H), 7.51 – 7.28 (m, 8H), 7.16 (q, *J* = 1.4 Hz, 1H), 7.09 (ddd, *J* = 8.6, 6.7, 3.0 Hz, 2H), 4.32 (ddd, *J* = 10.2, 7.4, 2.9 Hz, 1H), 3.34 (ddd, *J* = 18.0, 10.1, 5.3 Hz, 1H), 2.94 (ddd, *J* = 18.0, 11.1, 2.9 Hz, 1H), 1.85 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.2 (d, *J*_{C-P} = 12.7 Hz), 132.6 (d, *J*_{C-P} = 5.6 Hz), 132.2 (d, *J*_{C-P} = 1.9 Hz), 131.4 (d, *J*_{C-P} = 1.8 Hz), 131.1, 131.0 (d, *J*_{C-P} = 2.8 Hz), 130.9, 130.4 (d, *J*_{C-P} = 2.8 Hz), 130.3 (d, *J*_{C-P} = 8.5 Hz), 130.1, 130.0 (d, *J*_{C-P} = 9.0 Hz), 127.9 (d, *J*_{C-P} = 11.3 Hz), 127.7 (d, *J*_{C-P} = 6.8 Hz), 127.1 (d, *J*_{C-P} = 14.3 Hz), 127.0 (d, *J*_{C-P} = 68.6 Hz), 29.6. ³¹P NMR (162 MHz, CDCl₃) δ 33.32.

4-(Diphenylphosphoryl)-4-(pyridin-2-yl)butan-2-one (3o). 91% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.36 – 8.31 (m, 1H), 7.81 – 7.73 (m, 2H), 7.52 (ddd, *J* = 11.4, 8.3, 1.4 Hz, 2H), 7.47 – 7.44 (m, 1H), 7.41 (dt, *J* = 8.5, 3.3 Hz, 2H), 7.33 (td, *J* = 7.9, 1.8 Hz, 2H), 7.28 – 7.21 (m, 2H), 7.02 (d, *J* = 7.9 Hz, 1H), 6.96 – 6.91 (m, 1H), 4.45 (td, *J* = 10.9, 3.0 Hz, 1H), 3.61 (ddd, *J* = 18.0, 10.5, 5.7 Hz, 1H), 2.92 (ddd, *J* = 18.0, 10.4, 3.0 Hz, 1H), 1.96 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.5 (d, *J*_{C-P} = 13.0 Hz), 155.6 (d, *J*_{C-P} = 5.2 Hz), 149.1 (d, *J*_{C-P} = 2.1 Hz), 136.0 (d, *J*_{C-P} = 2.2 Hz), 132.0 (d, *J*_{C-P} = 50.7 Hz), 128.7

(d, $J_{C-P} = 11.6 \text{ Hz}$), 128.2 (d, $J_{C-P} = 11.8 \text{ Hz}$), 124.8 (d, $J_{C-P} = 3.8 \text{ Hz}$), 121.9 (d, $J_{C-P} = 2.5 \text{ Hz}$), 44.4 (d, $J_{C-P} = 65.4 \text{ Hz}$), 41.7, 30.2. ³¹P NMR (162 MHz, CDCl₃) δ 33.39.

4-(Diphenylphosphoryl)-4-(thiophen-2-yl)butan-2-one (3p). 82% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (ddd, *J* = 10.9, 8.0, 1.6 Hz, 2H), 7.53 – 7.39 (m, 5H), 7.32 (td, *J* = 7.3, 1.5 Hz, 1H), 7.27 – 7.20 (m, 2H), 6.98 (d, *J* = 3.8 Hz, 1H), 6.87 – 6.82 (m, 1H), 6.74 (d, *J* = 8.7 Hz, 1H), 4.51 (ddd, *J* = 10.6, 8.0, 2.9 Hz, 1H), 3.20 (ddd, *J* = 17.8, 10.2, 5.0 Hz, 1H), 2.86 (ddd, *J* = 17.8, 10.3, 2.9 Hz, 1H), 1.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.0 (d, *J*_{C-P} = 12.3 Hz), 137.5 (d, *J*_{C-P} = 6.3 Hz), 132.2 (d, *J*_{C-P} = 2.8 Hz), 131.7 (d, *J*_{C-P} = 2.8 Hz), 131.5 (d, *J*_{C-P} = 3.5 Hz), 131.3 (d, *J*_{C-P} = 8.6 Hz), 131.1 (d, *J*_{C-P} = 8.8 Hz), 130.5 (d, *J*_{C-P} = 9.5 Hz), 128.9 (d, *J*_{C-P} = 11.3 Hz), 128.2 (d, *J*_{C-P} = 11.8 Hz), 127.3 (d, *J*_{C-P} = 6.5 Hz), 126.8 (d, *J*_{C-P} = 2.6 Hz), 124.9 (d, *J*_{C-P} = 2.9 Hz), 44.4, 36.6 (d, *J*_{C-P} = 70.5 Hz), 30.6. ³¹P NMR (162 MHz, CDCl₃) δ 32.49.

4-(diphenylphosphoryl)-4-(furan-2-yl)butan-2-one (3q). 74% yield, yellow solid; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (ddd, *J* = 11.2, 8.2, 1.5 Hz, 2H), 7.51 (m, 3H), 7.47 – 7.38 (m, 3H), 7.32 (m, 2H), 7.18 – 7.09 (m, 1H), 6.14 (dd, *J* = 3.3, 1.9 Hz, 1H), 5.96 (d, *J* = 3.3 Hz, 1H), 4.46 (ddd, J = 10.7, 10.7, 3.2 Hz, 1H), 3.22 (ddd, J = 18.0, 10.5, 5.5 Hz, 1H), 2.96 (ddd, J = 18.0, 10.0, 3.2 Hz, 1H), 2.02 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.9 (d, *J*_{C-P} = 12.1 Hz), 148.9 (d, *J*_{C-P} = 6.5 Hz), 141.8 (d, *J*_{C-P} = 3.0 Hz), 132.2 (d, *J*_{C-P} = 2.8 Hz), 131.9 (d, *J*_{C-P} = 2.8 Hz), 131.4, 131.3, 130.9 (d, *J*_{C-P} = 18.7 Hz), 130.6 (d, *J*_{C-P} = 6.5 Hz), 128.8 (d, *J*_{C-P} = 11.5 Hz), 128.2 (d, *J*_{C-P} = 11.8 Hz), 110.8 (d, *J*_{C-P} = 2.7 Hz), 108.7 (d, *J*_{C-P} = 6.1 Hz), 40.8, 35.9 (d, *J*_{C-P} = 70.1 Hz), 30.2. ³¹P NMR (162 MHz, CDCl₃) δ 32.18.

4-Cyclohexyl-4-(diphenylphosphoryl)butan-2-one (3r). 61% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.82 – 7.66 (m, 4H), 7.44 – 7.27 (m, 6H), 3.19 – 3.03 (m, 1H), 2.72 – 2.63 (m, 2H), 2.07 – 1.95 (m, 1H), 1.85 (s, 3H), 1.59 (ddd, *J* = 33.0, 12.9, 2.6 Hz, 3H), 1.50 – 1.41 (m, 2H), 1.09 – 0.83 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 205.2 (d, *J*_{C-P} = 8.2 Hz), 132.3 (d, *J*_{C-P} = 9.1 Hz), 131.4 (d, *J*_{C-P} = 10.3 Hz), 130.5 (d, *J*_{C-P} = 5.2 Hz), 130.5, 130.0 (d, *J*_{C-P} = 8.6 Hz), 129.8 (d, *J*_{C-P} = 8.8 Hz), 127.6 (d, *J*_{C-P} = 22.1 Hz), 127.6, 36.9, 36.7 (d, *J*_{C-P} = 1.7 Hz), 35.6 (d, *J*_{C-P} = 71.8 Hz), 31.9 (d, *J*_{C-P} = 12.8 Hz), 28.8, 28.4 (d, *J*_{C-P} = 2.7 Hz), 25.6, 25.1 (d, *J*_{C-P} = 29.4 Hz). ³¹P NMR (162 MHz, CDCl₃) δ 36.60.

4-(Diphenylphosphoryl)nonan-2-one (3s). 75% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.83 – 7.68 (m, 4H), 7.45 – 7.33 (m, 6H), 3.09 (tdd, *J* = 10.5, 7.4, 3.9 Hz, 1H), 2.71 (ddd, *J* = 19.5, 15.9, 3.8 Hz, 1H), 2.60 – 2.53 (m, 1H), 1.91 (s, 3H), 1.54 (tdd, *J* = 14.4, 9.5, 4.5 Hz, 1H), 1.40 (ddd, *J* = 13.8, 9.2, 4.7 Hz, 1H), 1.24 – 1.14 (m, 1H), 1.13 – 0.98 (m, 5H), 0.76 – 0.65 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.0 (d, *J*_{C-P} = 9.8 Hz), 130.7 (d, *J*_{C-P} = 2.2 Hz), 130.7 (d, *J*_{C-P} = 7.3 Hz), 130.7 (d, *J*_{C-P} = 1.9 Hz), 129.9, 127.7 (d, *J*_{C-P} = 2.2 Hz), 127.6 (d, *J*_{C-P} = 2.4 Hz), 40.8, 30.6, 30.5 (d, *J*_{C-P} = 72.8 Hz), 29.0, 27.5 (d, *J*_{C-P} = 2.1 Hz), 26.3 (d, *J*_{C-P} = 10.8 Hz), 21.3, 12.9. ³¹P NMR (162 MHz, CDCl₃) δ 36.75.

4-(Diphenylphosphoryl)-6-phenylhex-5-en-2-one (3t). 65% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (ddd, *J* = 11.0, 8.1, 1.6 Hz, 2H), 7.69 (ddd, *J* = 11.1, 8.1, 1.5 Hz, 2H), 7.49 – 7.31 (m, 6H), 7.18 – 7.07 (m, 5H), 6.30 (dd, *J* = 15.9, 4.2 Hz, 1H), 5.98 (ddd, *J* = 15.8, 9.2, 6.4 Hz, 1H), 3.95 – 3.80 (m, 1H), 2.91 (ddd, *J* = 17.7, 9.8, 5.3 Hz, 1H), 2.83 – 2.72 (m, 1H), 2.00 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.2 (d, *J*_{C-P} = 12.8 Hz), 135.6 (d, *J*_{C-P} = 2.8 Hz), 134.2 (d, *J*_{C-P} = 11.5 Hz), 131.0 (d, *J*_{C-P} = 2.9 Hz), 131.1, 130.8 (d, *J*_{C-P} = 2.9 Hz), 130.4 (d, *J*_{C-P} = 8.8 Hz), 130.2 (d, *J*_{C-P} = 8.7 Hz), 129.9 (d, *J*_{C-P} = 1.7 Hz), 127.8 (d, *J*_{C-P} = 7.4 Hz), 40.7, 37.9 (d, *J*_{C-P} = 70.2 Hz), 29.6. ³¹P NMR (162 MHz, CDCl₃) δ 33.47.

4-(Diphenylphosphoryl)-6-phenylhex-5-yn-2-one (3u). 58% yield, yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 7.97 – 7.79 (m, 4H), 7.55 – 7.37 (m, 6H), 7.19 – 7.04 (m, 5H), 4.11 (ddd, *J* = 16.8, 10.5, 3.0 Hz, 1H), 3.09 (ddd, *J* = 17.5, 9.5, 3.0 Hz, 1H), 2.80 (ddd, *J* = 17.5, 10.5, 5.2 Hz, 1H), 2.13 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.3 (d, *J*_{C-P} = 11.8 Hz), 132.4 (d, *J*_{C-P} = 7.1 Hz), 132.4, 132.2 (d, *J*_{C-P} = 8.6 Hz), 131.6, 131.5, 131.5 (d, *J*_{C-P} = 6.2 Hz), 130.5 (d, *J*_{C-P} = 14.7 Hz), 129.5, 128.7 (d, *J*_{C-P} = 11.9 Hz), 128.4 (d, *J*_{C-P} = 11.8 Hz), 128.2, 122.6 (d, *J*_{C-P} = 3.4 Hz), 85.7 (d, *J*_{C-P} = 8.5 Hz), 85.2 (d, *J*_{C-P} = 7.7 Hz), 41.9, 30.2, 29.3 (d, *J*_{C-P} = 71.0 Hz). ³¹P NMR (162 MHz, CDCl₃) δ 31.72.

3-(Diphenylphosphoryl)-1-phenylhexan-1-one (3v). 91% yield, yellow solid; ¹H NMR (400 MHz, CDCl₃) δ 7.85 – 7.71 (m, 6H), 7.43 (d, *J* = 11.0 Hz, 4H), 7.32 (d, *J* = 6.8 Hz, 5H), 3.38 (tt, *J* = 6.4, 3.0 Hz, 1H), 3.29 – 3.07 (m, 2H), 1.55 (dddd, *J* = 24.4, 14.0, 7.7, 4.3 Hz, 2H), 1.27 – 1.04 (m, 2H), 0.69 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ

197.6 (d, $J_{C-P} = 10.9 \text{ Hz}$), 136.4, 133.4, 132.8 (d, $J_{C-P} = 20.5 \text{ Hz}$), 131.9, 131.7 (d, $J_{C-P} = 4.7 \text{ Hz}$), 131.7, 131.0 (d, $J_{C-P} = 1.5 \text{ Hz}$), 130.9 (d, $J_{C-P} = 1.4 \text{ Hz}$), 128.8 (d, $J_{C-P} = 1.5 \text{ Hz}$), 128.7 (d, $J_{C-P} = 1.6 \text{ Hz}$), 128.6, 128.1, 37.1, 31.5 (d, $J_{C-P} = 73.1 \text{ Hz}$), 30.9 (d, $J_{C-P} = 2.1 \text{ Hz}$), 21.0 (d, $J_{C-P} = 11.0 \text{ Hz}$), 14.0. ³¹P NMR (162 MHz, CDCl₃) δ 37.35.

1-(Diphenylphosphoryl)-4,4-dimethyl-1-phenylpentan-3-one (3w). 97% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (ddd, *J* = 10.7, 7.6, 1.9 Hz, 2H), 7.52 – 7.40 (m, 3H), 7.39 – 7.30 (m, 2H), 7.23 (ddd, *J* = 7.2, 5.9, 1.6 Hz, 3H), 7.14 (ddd, *J* = 8.5, 6.7, 3.0 Hz, 2H), 7.10 – 6.99 (m, 3H), 4.20 (ddd, *J* = 9.7, 6.6, 2.7 Hz, 1H), 3.40 (ddd, *J* = 17.8, 10.1, 4.7 Hz, 1H), 2.76 (ddd, *J* = 17.8, 11.5, 2.7 Hz, 1H), 0.80 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 211.5 (d, *J*_{C-P} = 12.1 Hz), 135.1 (d, *J*_{C-P} = 5.4 Hz), 131.2 (d, *J*_{C-P} = 36.7 Hz), 130.9 (d, *J*_{C-P} = 2.6 Hz), 130.3 (d, *J*_{C-P} = 3.3 Hz), 130.3 (d, *J*_{C-P} = 8.4 Hz), 130.3 (d, *J*_{C-P} = 31.1 Hz), 129.9 (d, *J*_{C-P} = 8.8 Hz), 128.9 (d, *J*_{C-P} = 5.8 Hz), 127.8 (d, *J*_{C-P} = 11.3 Hz), 127.2 (d, *J*_{C-P} = 1.9 Hz), 127.0 (d, *J*_{C-P} = 11.8 Hz), 126.0 (d, *J*_{C-P} = 2.4 Hz), 43.1, 40.1 (d, *J*_{C-P} = 69.4 Hz), 36.5, 24.7. ³¹P NMR (162 MHz, CDCl₃) δ 34.14.

3-(Diphenylphosphoryl)-1,3-diphenylpropan-1-one (3x). 98% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.00 – 7.85 (m, 2H), 7.76 (d, J = 7.7 Hz, 2H), 7.52 – 7.34 (m, 6H), 7.28 (dq, J = 12.7, 7.4, 5.3 Hz, 5H), 7.15 (dd, J = 8.0, 2.9 Hz, 2H), 7.05 (dt, J = 14.2, 7.2 Hz, 3H), 4.40 (ddd, J = 9.9, 6.7, 2.4 Hz, 1H), 3.94 (ddd, J = 18.2, 10.3, 4.4 Hz, 1H), 3.31 (ddd, J = 18.2, 11.3, 2.5 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 196.7 (d, J_{C-P} = 13.2 Hz), 136.4, 136.0 (d, J_{C-P} = 5.6 Hz), 133.4, 132.1 (d, J_{C-P} = 25.7 Hz), 132.0 (d, J_{C-P} = 2.7 Hz), 131.4 (d, J_{C-P} = 2.9 Hz), 131.3 (d, J_{C-P} = 8.5 Hz), 131.2, 131.0 (d, J_{C-P} = 8.9 Hz), 129.9 (d, $J_{C-P} = 5.6 \text{ Hz}$), 129.0 (d, $J_{C-P} = 11.3 \text{ Hz}$), 128.6, 128.3 (d, $J_{C-P} = 2.0 \text{ Hz}$), 128.1, 128.0, 127.1 (d, J_{C-P} = 2.6 Hz), 41.1 (d, J_{C-P} = 69.0 Hz), 39.0. ³¹P NMR (162 MHz, CDCl₃) δ 34.24. 3-(Diphenylphosphoryl)-3-(4-methoxyphenyl)-1-phenylpropan-1-one (3y). 97% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.95 – 7.83 (m, 2H), 7.75 (dd, J = 7.7, 2.1 Hz, 2H), 7.40 (ddt, J = 11.5, 5.5, 2.0 Hz, 6H), 7.30 – 7.16 (m, 7H), 6.66 – 6.52 (m, 2H), 4.35 (ddd, *J* = 10.4, 6.9, 2.4 Hz, 1H), 3.88 (ddd, *J* = 18.0, 10.4, 4.3 Hz, 1H), 3.59 (s, 3H), 3.26 (ddd, J = 18.0, 10.9, 2.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 196.8 (d, $J_{C-P} = 13.5$ Hz), 158.6 (d, $J_{C-P} = 2.3 \text{ Hz}$), 136.5, 133.3, 132.3 (d, $J_{C-P} = 23.5 \text{ Hz}$), 132.0 (d, $J_{C-P} = 2.8 \text{ Hz}$), 131.4 (d, J_{C-P} = 2.9 Hz), 131.3 (d, J_{C-P} = 8.5 Hz), 131.2, 131.0 (d, J_{C-P} = 8.8 Hz), 130.9 (d,

 $J_{C-P} = 5.8 \text{ Hz}$), 128.9 (d, $J_{C-P} = 11.1 \text{ Hz}$), 128.6, 128.1 (d, $J_{C-P} = 11.6 \text{ Hz}$), 128.1, 127.8 (d, $J_{C-P} = 5.8 \text{ Hz}$), 113.8 (d, $J_{C-P} = 2.2 \text{ Hz}$), 55.1, 40.2 (d, $J_{C-P} = 70.1 \text{ Hz}$), 39.1. ³¹P NMR (162 MHz, CDCl₃) δ 34.22.

3-(Diphenylphosphoryl)-3-(4-fluorophenyl)-1-phenylpropan-1-one (3z). 94% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (ddd, *J* = 10.7, 7.4, 2.0 Hz, 2H), 7.79 – 7.69 (m, 2H), 7.52 – 7.36 (m, 6H), 7.34 – 7.24 (m, 5H), 7.22 – 7.19 (m, 2H), 6.76 (t, *J* = 8.7 Hz, 2H), 4.38 (ddd, *J* = 10.6, 6.8, 2.4 Hz, 1H), 3.89 (ddd, *J* = 18.1, 10.5, 4.2 Hz, 1H), 3.28 (ddd, *J* = 18.1, 10.8, 2.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 195.6 (d, *J*_{C-P} = 13.3 Hz), 160.9 (dd, *J*_{C-F} = 246.1, 2.6 Hz), 135.3, 132.4, 131.1 (d, *J*_{C-P} = 3.0 Hz), 130.8 (d, *J*_{C-P} = 3.3 Hz), 130.7, 130.7, 130.6 (d, *J*_{C-P} = 2.8 Hz), 130.4, 130.3 (d, *J*_{C-P} = 2.3 Hz), 130.3, 130.2, 129.9 (d, *J*_{C-P} = 29.1 Hz), 129.9 (d, *J*_{C-P} = 9.0 Hz), 128.0 (d, *J*_{C-P} = 11.2 Hz), 127.3 (d, *J*_{C-P} = 52.1 Hz), 127.2 (d, *J*_{C-P} = 11.8 Hz), 114.2 (dd, *J*_{C-F} = 21.3, 1.9 Hz), 39.3 (d, *J*_{C-P} = 69.4 Hz), 38.1. ³¹P NMR (162 MHz, CDCl₃) δ 33.99. ¹⁹F NMR (376 MHz, CDCl₃) δ -115.30

3-(Diphenylphosphoryl)-3-(4-chlorophenyl)-1-phenylpropan-1-one (3aa). 95% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.95 – 7.84 (m, 2H), 7.80 – 7.70 (m, 2H), 7.43 (dddd, *J* = 12.7, 6.5, 3.3, 1.6 Hz, 6H), 7.34 – 7.19 (m, 7H), 7.08 – 6.98 (m, 2H), 4.37 (ddd, *J* = 10.5, 6.8, 2.4 Hz, 1H), 3.88 (ddd, *J* = 18.1, 10.5, 4.3 Hz, 1H), 3.28 (ddd, *J* = 18.2, 10.8, 2.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 195.4 (d, *J*_{C-P} = 13.2 Hz), 135.2, 133.6 (d, *J*_{C-P} = 5.6 Hz), 132.5, 132.0 (d, *J*_{C-P} = 2.9 Hz), 131.1 (d, *J*_{C-P} = 2.7 Hz), 130.8 (d, *J*_{C-P} = 25.6 Hz), 130.6 (d, *J*_{C-P} = 2.7 Hz), 130.1 (d, *J*_{C-P} = 16.1 Hz), 130.1 (d, *J*_{C-P} = 1.8 Hz), 129.9 (d, *J*_{C-P} = 1.8 Hz), 129.7, 128.0 (d, *J*_{C-P} = 68.9 Hz), 38.0. ³¹P NMR (162 MHz, CDCl₃) δ 33.75.

3-(Diphenylphosphoryl)-1-(4-methoxyphenyl)-3-phenylpropan-1-one (**3ab**). 97% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.91 (td, *J* = 8.2, 7.7, 3.6 Hz, 2H), 7.75 (d, *J* = 8.6 Hz, 2H), 7.47 – 7.35 (m, 5H), 7.27 (dd, *J* = 25.6, 7.5 Hz, 3H), 7.16 (dt, *J* = 7.8, 3.8 Hz, 2H), 7.04 (dt, *J* = 14.8, 7.2 Hz, 3H), 6.75 (d, *J* = 8.5 Hz, 2H), 4.40 (ddd, *J* = 9.9, 6.7, 2.3 Hz, 1H), 3.89 (ddd, *J* = 18.0, 10.4, 4.3 Hz, 1H), 3.72 (s, 3H), 3.24 (ddd, *J* = 17.9, 11.4, 2.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 194.1 (d, *J*_{C-P} = 13.2 Hz), 162.6, 135.1 (d, *J*_{C-P} = 5.6 Hz), 131.2 (d, *J*_{C-P} = 30.3 Hz), 130.9 (d, *J*_{C-P} = 5.8 Hz), 128.5, 127.9 (d, *J*_{C-P} = 11.1

Hz), 127.2 (d, $J_{C-P} = 2.0$ Hz), 127.0 (d, $J_{C-P} = 11.8$ Hz), 126.0(d, $J_{C-P} = 2.5$ Hz), 112.6, 54.4, 40.1 (d, $J_{C-P} = 69.2$ Hz), 37.5. ³¹P NMR (162 MHz, CDCl₃) δ 34.35.

3-(Diphenylphosphoryl)-1-(4-fluorophenyl)-3-phenylpropan-1-one (3ac). 92% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.95 – 7.85 (m, 2H), 7.78 (dd, *J* = 8.9, 5.3 Hz, 2H), 7.49 – 7.35 (m, 5H), 7.32 – 7.23 (m, 3H), 7.16 (dd, *J* = 7.2, 3.1 Hz, 2H), 7.10 – 6.99 (m, 3H), 6.96 (t, *J* = 8.7 Hz, 2H), 4.37 (ddd, *J* = 9.8, 6.9, 2.6 Hz, 1H), 3.89 (ddd, *J* = 18.0, 10.3, 4.7 Hz, 1H), 3.29 (ddd, *J* = 18.0, 11.1, 2.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 194.2 (d, *J*_{C-P} = 13.4 Hz), 164.8 (d, *J*_{C-F} = 255.4 Hz), 134.9 (d, *J*_{C-P} = 5.5 Hz), 131.9 (d, *J*_{C-P} = 2.8 Hz), 131.0 (d, *J*_{C-P} = 2.9 Hz), 130.9, 130.4 (d, *J*_{C-P} = 2.8 Hz), 130.3 (d, *J*_{C-P} = 8.5 Hz), 130.0 (d, *J*_{C-P} = 8.9 Hz), 129.8 (d, *J*_{C-P} = 9.4 Hz), 128.8 (d, *J*_{C-P} = 5.7 Hz), 127.9 (d, *J*_{C-P} = 11.2 Hz), 127.3 (d, *J*_{C-P} = 2.0 Hz), 127.1 (d, *J*_{C-P} = 11.8 Hz), 126.1 (d, *J*_{C-P} = 2.5 Hz), 114.6 (d, *J*_{C-P} = 21.9 Hz), 40.2 (d, *J*_{C-P} = 69.0 Hz), 37.9. ³¹P NMR (162 MHz, CDCl₃) δ 34.15. ¹⁹F NMR (376 MHz, CDCl₃) δ -104.56.

1-(Diphenylphosphoryl)-3-(4-chlorophenyl)-3-phenylpropan-1-one (3ad). 97% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.03 – 7.92 (m, 2H), 7.76 (d, *J* = 8.6 Hz, 2H), 7.57 – 7.41 (m, 5H), 7.40 – 7.28 (m, 5H), 7.23 (dd, *J* = 7.9, 2.6 Hz, 2H), 7.18 – 7.03 (m, 3H), 4.43 (ddd, *J* = 9.9, 6.9, 2.6 Hz, 1H), 3.95 (ddd, *J* = 18.0, 10.3, 4.8 Hz, 1H), 3.36 (ddd, *J* = 18.0, 11.1, 2.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 195.7 (d, *J*_{C-P} = 13.2 Hz), 139.9, 135.8 (d, *J*_{C-P} = 5.5 Hz), 134.7, 132.1 (d, *J*_{C-P} = 2.9 Hz), 131.9, 131.5 (d, *J*_{C-P} = 2.8 Hz), 131.3 (d, *J*_{C-P} = 8.4 Hz), 131.1, 131.0 (d, *J*_{C-P} = 9.0 Hz), 129.8 (d, *J*_{C-P} = 5.6 Hz), 129.5, 129.0 (d, *J*_{C-P} = 11.3 Hz), 128.9, 128.4 (d, *J*_{C-P} = 1.9 Hz), 128.1 (d, *J*_{C-P} = 11.8 Hz), 127.2 (d, *J*_{C-P} = 2.5 Hz), 41.2 (d, *J*_{C-P} = 68.9 Hz), 39.0. ³¹P NMR (162 MHz, CDCl₃) δ 34.02.

4-(Di-p-tolylphosphoryl)-4-phenylbutan-2-one (3ae). 95% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.77 – 7.67 (m, 2H), 7.23 (tt, *J* = 8.1, 3.5 Hz, 6H), 7.12 – 7.01 (m, 3H), 6.95 (dd, *J* = 8.0, 2.8 Hz, 2H), 4.09 (ddd, *J* = 10.3, 7.5, 2.9 Hz, 1H), 3.23 (ddd, *J* = 17.9, 10.2, 5.3 Hz, 1H), 2.85 (ddd, *J* = 17.9, 11.1, 2.9 Hz, 1H), 2.33 (s, 3H), 2.17 (s, 3H), 1.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.5 (d, *J*_{C-P} = 12.8 Hz), 141.4 (d, *J*_{C-P} = 2.8 Hz), 140.7 (d, *J*_{C-P} = 2.9 Hz), 135.1 (d, *J*_{C-P} = 5.5 Hz), 130.3 (d, *J*_{C-P} = 8.8 Hz), 130.0 (d, *J*_{C-P} = 9.2 Hz), 128.7 (d, *J*_{C-P} = 5.7 Hz), 128.6 (d, *J*_{C-P} = 11.6 Hz), 127.9 (d, *J*_{C-P} = 11.0 Hz), 127.8 (d, *J*_{C-P} = 12.2 Hz), 127.3 (d, *J*_{C-P} = 2.0 Hz), 126.9 (d, *J*_{C-P} = 5.6 Hz), 126.0 (d, *J*_{C-P} =

2.5 Hz), 42.7, 40.3 (d, J_{C-P} = 68.8 Hz), 29.6, 20.6 (d, J_{C-P} = 1.3 Hz), 20.4 (d, J_{C-P} = 1.3 Hz). ³¹P NMR (162 MHz, CDCl₃) δ 33.96.

4-(Bis(4-chlorophenyl)phosphoryl)-4-phenylbutan-2-one (3af). 97% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.77 (dd, *J* = 10.4, 8.4 Hz, 2H), 7.49 – 7.38 (m, 2H), 7.32 – 7.19 (m, 4H), 7.17 – 6.99 (m, 5H), 4.12 (ddd, *J* = 10.0, 7.1, 2.9 Hz, 1H), 3.23 (ddd, *J* = 18.0, 9.8, 5.5 Hz, 1H), 2.85 (ddd, *J* = 18.1, 11.8, 3.0 Hz, 1H), 1.90 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.9 (d, *J*_{C-P} = 12.7 Hz), 139.0 (d, *J*_{C-P} = 3.3 Hz), 138.3 (d, *J*_{C-P} = 3.4 Hz), 135.3, 132.7 (d, *J*_{C-P} = 9.4 Hz), 132.3 (d, *J*_{C-P} = 9.6 Hz), 130.1 (d, *J*_{C-P} = 18.3 Hz), 129.7 (d, *J*_{C-P} = 5.8 Hz), 129.4 (d, *J*_{C-P} = 11.8 Hz), 129.2 (d, *J*_{C-P} = 12.2 Hz), 128.6 (d, *J*_{C-P} = 2.0 Hz), 128.6 (d, *J*_{C-P} = 12.3 Hz), 127.5 (d, *J*_{C-P} = 2.5 Hz), 43.5, 40.9 (d, *J*_{C-P} = 69.8 Hz), 30.6. ³¹P NMR (162 MHz, CDCl₃) δ 32.76.

4-(Bis(4-methoxyphenyl)phosphoryl)-4-phenylbutan-2-one (3ag). 95% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.87 – 7.77 (m, 2H), 7.34 – 7.26 (m, 4H), 7.21 – 7.10 (m, 3H), 7.02 (dd, *J* = 8.9, 2.3 Hz, 2H), 6.78 – 6.68 (m, 2H), 4.12 (ddd, *J* = 10.5, 7.8, 3.0 Hz, 1H), 3.85 (s, 3H), 3.73 (s, 3H), 3.29 (ddd, *J* = 17.8, 10.2, 5.4 Hz, 1H), 2.95 (ddd, *J* = 17.9, 11.2, 2.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 205.6 (d, *J*_{C-P} = 12.8 Hz), 162.5 (d, *J*_{C-P} = 2.9 Hz), 161.9 (d, *J*_{C-P} = 2.9 Hz), 136.2 (d, *J*_{C-P} = 5.5 Hz), 133.1 (d, *J*_{C-P} = 9.7 Hz), 132.9 (d, *J*_{C-P} = 10.1 Hz), 129.7 (d, *J*_{C-P} = 5.5 Hz), 128.3 (d, *J*_{C-P} = 1.9 Hz), 127.0 (d, *J*_{C-P} = 2.5 Hz), 123.3 (d, *J*_{C-P} = 48.1 Hz), 122.3 (d, *J*_{C-P} = 69.3 Hz), 30.6. ³¹P NMR (162 MHz, CDCl₃) δ 33.78.

4-(Bis(4-ethylphenyl)phosphoryl)-4-phenylbutan-2-one (3ah). 51% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (dd, *J* = 10.5, 7.9 Hz, 2H), 7.30 – 7.20 (m, 6H), 7.13 – 7.02 (m, 3H), 6.98 (dd, *J* = 8.2, 2.8 Hz, 2H), 4.10 (ddd, *J* = 10.3, 7.5, 2.9 Hz, 1H), 3.24 (ddd, *J* = 17.8, 10.3, 5.3 Hz, 1H), 2.86 (ddd, *J* = 17.9, 11.0, 2.9 Hz, 1H), 2.63 (q, *J* = 7.6 Hz, 2H), 2.48 (q, *J* = 7.6 Hz, 2H), 1.87 (s, 3H), 1.18 (t, *J* = 7.6 Hz, 3H), 1.06 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.6 (d, *J*_{C-P} = 12.8 Hz), 147.5 (d, *J*_{C-P} = 2.7 Hz), 146.9 (d, *J*_{C-P} = 2.8 Hz), 135.1 (d, *J*_{C-P} = 5.5 Hz), 130.4 (d, *J*_{C-P} = 8.8 Hz), 130.1 (d, *J*_{C-P} = 9.2 Hz), 128.7 (d, *J*_{C-P} = 5.6 Hz), 128.0 (d, *J*_{C-P} = 13.2 Hz), 127.4 (d, *J*_{C-P} = 11.7 Hz), 127.3 (d, *J*_{C-P} = 1.9 Hz), 127.0 (d, J_{C-P} = 7.7 Hz), 126.6 (d, J_{C-P} = 12.1 Hz), 126.0 (d, J_{C-P} = 2.5 Hz), 42.6, 40.3 (d, J_{C-P} = 68.6 Hz), 29.6, 27.8, 27.7, 14.1, 14.0. ³¹P NMR (162 MHz, CDCl₃) δ 33.93. **4-(Di-o-tolylphosphoryl)-4-phenylbutan-2-one (3ai).** 53% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.72 (dd, J = 10.7, 6.9 Hz, 1H), 7.45 – 7.32 (m, 2H), 7.26 (d, J = 8.0 Hz, 3H), 7.16 – 7.00 (m, 5H), 6.94 (t, J = 7.6 Hz, 1H), 6.85 (dd, J = 7.7, 4.4 Hz, 1H), 4.36 (ddd, J = 9.8, 6.8, 2.5 Hz, 1H), 3.40 (ddd, J = 18.2, 10.1, 4.3 Hz, 1H), 3.15 (ddd, J = 18.2, 10.7, 2.5 Hz, 1H), 2.28 (s, 3H), 2.04 (s, 3H), 1.95 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 204.8 (d, J_{C-P} = 12.6 Hz), 142.2 (d, J_{C-P} = 7.4 Hz), 140.8 (d, J_{C-P} = 8.4 Hz), 135.6 (d, J_{C-P} = 5.0 Hz), 131.6 (d, J_{C-P} = 5.5 Hz), 131.4 (d, J_{C-P} = 5.1 Hz), 130.8 (d, J_{C-P} = 2.5 Hz), 130.4, 130.3 (d, J_{C-P} = 2.2 Hz), 130.2 (d, J_{C-P} = 6.2 Hz), 130.1 (d, J_{C-P} = 10.1 Hz), 129.5, 128.6 (d, J_{C-P} = 5.8 Hz), 127.3 (d, J_{C-P} = 1.9 Hz), 126.0 (d, J_{C-P} = 2.4 Hz), 124.5 (d, J_{C-P} = 11.3 Hz), 124.0 (d, J_{C-P} = 12.1 Hz), 43.5, 38.5 (d, J_{C-P} = 69.4 Hz), 29.8, 20.3 (d, J_{C-P} = 4.1 Hz), 20.0 (d, J_{C-P} = 3.5 Hz). ³¹P NMR (162 MHz, CDCl₃) δ 37.17.

4-(Di-m-tolylphosphoryl)-4-phenylbutan-2-one (3aj). 74% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 11.2 Hz, 1H), 7.64 – 7.55 (m, 1H), 7.37 – 7.20 (m, 4H), 7.17 – 7.00 (m, 7H), 4.11 (ddd, *J* = 10.2, 7.3, 2.9 Hz, 1H), 3.25 (ddd, *J* = 17.8, 10.3, 5.3 Hz, 1H), 2.84 (ddd, *J* = 17.9, 11.0, 2.9 Hz, 1H), 2.33 (s, 3H), 2.10 (s, 3H), 1.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.4 (d, *J*_{C-P} = 12.8 Hz), 138.8 (d, *J*_{C-P} = 11.1 Hz), 137.9 (d, *J*_{C-P} = 11.7 Hz), 136.0 (d, *J*_{C-P} = 5.5 Hz), 132.8 (d, *J*_{C-P} = 2.9 Hz), 132.2 (d, *J*_{C-P} = 2.9 Hz), 132.0 (d, *J*_{C-P} = 8.1 Hz), 131.8 (d, *J*_{C-P} = 3.3 Hz), 131.8 (d, *J*_{C-P} = 8.2 Hz), 130.8 (d, *J*_{C-P} = 2.1 Hz), 129.8 (d, *J*_{C-P} = 5.6 Hz), 128.7 (d, *J*_{C-P} = 12.0 Hz), 128.3 (d, *J*_{C-P} = 2.0 Hz), 128.1 (d, *J*_{C-P} = 8.9 Hz), 127.9 (d, *J*_{C-P} = 6.7 Hz), 127.8 (d, *J*_{C-P} = 3.6 Hz), 127.1 (d, *J*_{C-P} = 2.5 Hz), 43.5, 41.2 (d, *J*_{C-P} = 68.3 Hz), 30.6, 21.5, 21.2. ³¹P NMR (162 MHz, CDCl₃) δ 33.94.

4-(Bis(3,5-dimethylphenyl)phosphoryl)-4-phenylbutan-2-one (3ak). 53% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.43 (dd, *J* = 11.1, 1.7 Hz, 2H), 7.27 – 7.20 (m, 2H), 7.13 – 7.01 (m, 4H), 6.94 (dd, *J* = 11.6, 1.6 Hz, 2H), 6.86 (s, 1H), 4.08 (ddd, *J* = 10.3, 7.4, 2.9 Hz, 1H), 3.23 (ddd, *J* = 17.8, 10.3, 5.2 Hz, 1H), 2.83 (ddd, *J* = 17.9, 10.9, 2.9 Hz, 1H), 2.30 (s, 6H), 2.09 (s, 6H), 1.87 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.6 (d, *J*_{C-P} = 12.9 Hz), 138.5 (d, *J*_{C-P} = 11.9 Hz), 137.6 (d, *J*_{C-P} = 12.4 Hz), 136.2 (d, *J*_{C-P} = 5.5 Hz), 133.7 (d, *J*_{C-P} = 2.9 Hz), 133.1 (d, *J*_{C-P} = 2.9 Hz), 131.7 (d, *J*_{C-P} = 7.3 Hz), 130.8 (d, *J*_{C-P} = 12.6 Hz),

129.8 (d, $J_{C-P} = 5.6 \text{ Hz}$), 128.9 (d, $J_{C-P} = 8.6 \text{ Hz}$), 128.7 (d, $J_{C-P} = 8.8 \text{ Hz}$), 128.2 (d, $J_{C-P} = 1.9 \text{ Hz}$), 127.0 (d, $J_{C-P} = 2.4 \text{ Hz}$), 43.6, 41.2 (d, $J_{C-P} = 68.0 \text{ Hz}$), 30.6, 21.4, 21.1. ³¹P NMR (162 MHz, CDCl₃) δ 34.11.

4-(Di(naphthalen-2-yl)phosphoryl)-4-phenylbutan-2-one (3am). 31% yield, white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 12.7 Hz, 1H), 8.01 (d, *J* = 13.2 Hz, 1H), 7.95 – 7.88 (m, 2H), 7.86 – 7.80 (m, 2H), 7.65 (q, *J* = 8.0 Hz, 3H), 7.56 – 7.47 (m, 2H), 7.45 – 7.28 (m, 5H), 7.06 (dt, *J* = 13.1, 6.9 Hz, 3H), 4.39 (ddd, *J* = 10.2, 7.2, 2.9 Hz, 1H), 3.33 (ddd, *J* = 17.9, 10.2, 5.2 Hz, 1H), 2.94 (ddd, *J* = 18.0, 11.2, 2.9 Hz, 1H), 1.86 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 205.3 (d, *J*_{C-P} = 12.8 Hz), 135.9 (d, *J*_{C-P} = 5.6 Hz), 134.7 (d, *J*_{C-P} = 2.2 Hz), 134.4 (d, *J*_{C-P} = 2.5 Hz), 133.7 (d, *J*_{C-P} = 7.5 Hz), 133.3 (d, *J*_{C-P} = 7.8 Hz), 132.7 (d, *J*_{C-P} = 17.7 Hz), 128.9, 128.8, 128.5 (d, *J*_{C-P} = 1.9 Hz), 128.4, 128.2, 128.0, 127.9, 127.9, 127.8, 127.7, 127.2 (d, *J*_{C-P} = 2.5 Hz), 127.1, 126.7, 125.8 (d, *J*_{C-P} = 10.0 Hz), 43.7, 41.0 (d, *J*_{C-P} = 68.9 Hz), 30.6. ³¹P NMR (162 MHz, CDCl₃) δ 34.00.


Figure S3.2 ¹³C NMR spectrum of 3a (101 MHz, CDCl₃).





Figure S3.3 ³¹P NMR spectrum of 3a (162 MHz, CDCl₃).





Figure S3.4 ¹H NMR spectrum of **3b** (400 MHz, CDCl₃).



fl (ppm)

Figure S3.6 $^{\rm 31}P$ NMR spectrum of 3b (162 MHz, CDCl₃).



Figure S3.7 ¹H NMR spectrum of 3c (400 MHz, CDCl₃).



Figure S3.8 13 C NMR spectrum of 3c (101 MHz, CDCl₃).





Figure S3.9 ³¹P NMR spectrum of **3c** (162 MHz, CDCl₃).



Figure S3.10 ¹H NMR spectrum of 3d (400 MHz, CDCl₃).



Figure S3.12 ³¹P NMR spectrum of 3d (162 MHz, CDCl₃).



Figure S3.14 ¹³C NMR spectrum of **3e** (101 MHz, CDCl₃).



Figure S3.15 ³¹P NMR spectrum of **3e** (162 MHz, CDCl₃).

140 120

100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)



Figure S3.16 ¹H NMR spectrum of 3f (400 MHz, CDCl₃).





Figure S3.18 ³¹P NMR spectrum of 3f (162 MHz, CDCl₃).



-90 -92 -94 -96 -98 -100 -102 -104 -106 -108 -110 -112 -114 -116 -118 -120 -122 -124 -126 -128 -130 -132 -134 -136 -138 -140 -142 -144 -146 -148 -150 fl (ppm)





Figure S3.20 ¹H NMR spectrum of 3g (400 MHz, CDCl₃).







Figure S3.24 ¹³C NMR spectrum of **3h** (101 MHz, DMSO- d_6).







Figure S3.26 ¹H NMR spectrum of 3i (400 MHz, CDCl₃).



Figure S3.28 ³¹P NMR spectrum of 3i (162 MHz, CDCl₃).



Figure S3.30 ¹³C NMR spectrum of 3j (101 MHz, CDCl₃).





Figure S3.31 ³¹P NMR spectrum of 3j (162 MHz, CDCl₃).





Figure S3.32 ¹H NMR spectrum of 3k (400 MHz, CDCl₃).



Figure S3.34 ³¹P NMR spectrum of 3k (162 MHz, CDCl₃).





Figure S3.36 13 C NMR spectrum of 3I (101 MHz, CDCl₃).





-40 -42 -44 -46 -48 -50 -52 -54 -56 -58 -60 -62 -64 -66 -68 -70 -72 -74 -76 -78 -80 -82 -84 -86 -88 -90 -92 -94 -96 -98 -100 -102 -104 f1 (ppa)

Figure S3.38 ¹⁹F NMR spectrum of 3I (376 MHz, CDCl₃).



Figure S3.40¹³C NMR spectrum of 3m (101 MHz, CDCl₃).





Figure S3.41 ^{31}P NMR spectrum of 3m (162 MHz, CDCl₃).





Figure S3.42 ¹H NMR spectrum of 3n (400 MHz, CDCl₃).



140 120 100 80 60 40 20 0 -20 -40 -60 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)

Figure S3.44 ³¹P NMR spectrum of 3n (162 MHz, CDCl₃).



Figure S3.46¹³C NMR spectrum of **30** (101 MHz, CDCl₃).



140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)



Figure S3.48 1 H NMR spectrum of 3p (400 MHz, CDCl₃).





Figure S3.49¹³C NMR spectrum of **3p** (101 MHz, CDCl₃).



140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)

Figure S3.50 ³¹P NMR spectrum of **3p** (162 MHz, CDCl₃).



Figure S3.52 ¹³C NMR spectrum of 3q (101 MHz, CDCl₃).





Figure S3.54 ¹H NMR spectrum of 3r (400 MHz, CDCl₃).



140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)

Figure S3.56 ³¹P NMR spectrum of 3r (162 MHz, CDCl₃).





210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (ppm)

-10 -2

Figure S3.58 ¹³C NMR spectrum of 3s (101 MHz, CDCl₃).





Figure S3.60 ¹H NMR spectrum of 3t (400 MHz, CDCl₃).



Figure S3.62 ³¹P NMR spectrum of **3t** (162 MHz, CDCl₃).



Figure S3.64 ¹³C NMR spectrum of **3u** (101 MHz, CDCl₃).



Figure S3.66 ¹H NMR spectrum of **3v** (400 MHz, CDCl₃).





Figure S3.68 ³¹P NMR spectrum of 3v (162 MHz, CDCl₃).



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 f1 (ppm)

Figure S3.70¹³C NMR spectrum of **3w** (101 MHz, CDCl₃).







Figure S3.72 ¹H NMR spectrum of 3x (400 MHz, CDCl₃).




Figure S3.74 ³¹P NMR spectrum of 3x (162 MHz, CDCl₃).



Figure S3.76 ¹³C NMR spectrum of 3y (101 MHz, CDCl₃).





Figure S3.78 ¹H NMR spectrum of 3z (400 MHz, CDCl₃).



140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)

Figure S3.80 ³¹P NMR spectrum of 3z (162 MHz, CDCl₃).



Figure S3.82 1 H NMR spectrum of 3aa (400 MHz, CDCl₃).



140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)

Figure S3.84 ³¹P NMR spectrum of 3aa (162 MHz, CDCl₃).



Figure S3.86 ¹³C NMR spectrum of **3ab** (101 MHz, CDCl₃).



Figure S3.87 ³¹P NMR spectrum of **3ab** (162 MHz, CDCl₃).

140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)



Figure S3.88 ¹H NMR spectrum of 3ac (400 MHz, CDCl₃).



Figure S3.90 ³¹P NMR spectrum of **3ac** (162 MHz, CDCl₃).



Figure S3.92 ¹H NMR spectrum of 3ad (400 MHz, CDCl₃).



Figure S3.94 ³¹P NMR spectrum of 3ad (162 MHz, CDCl₃).



Figure S3.96 ¹³C NMR spectrum of 3ae (101 MHz, CDCl₃).





Figure S3.98 ¹H NMR spectrum of 3af (400 MHz, CDCl₃).



140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm)

Figure S3.100 ^{31}P NMR spectrum of 3af (162 MHz, CDCl₃).



Figure S3.102 ¹³C NMR spectrum of 3ag (101 MHz, CDCl₃).





Figure S3.104 ¹H NMR spectrum of **3ah** (400 MHz, CDCl₃).



Figure S3.106 ³¹P NMR spectrum of **3ah** (162 MHz, CDCl₃).



Figure S3.108 ¹³C NMR spectrum of 3ai (101 MHz, CDCl₃).





Figure S3.110 ¹H NMR spectrum of 3aj (400 MHz, CDCl₃).



Figure S3.112 ³¹P NMR spectrum of 3aj (162 MHz, CDCl₃).



Figure S3.114 ¹³C NMR spectrum of **3ak** (101 MHz, CDCl₃).





Figure S3.116 1 H NMR spectrum of 3am (400 MHz, CDCl₃).



Figure S3.118 ³¹P NMR spectrum of **3am** (162 MHz, CDCl₃).

4. Substrate Scope Limitations and Observed Challenges

During the exploration of the substrate scope, we also encountered several limitations, as illustrated in **Scheme S4.1**. For instance, reactions (1) and (2) resulted in low yields, likely due to severe steric hindrance associated with the substituents. Reactions (3) through (6) led to the formation of multiple side products, and no clear chemoselectivity was observed under the standard conditions. These examples underline the steric and electronic sensitivity of the current catalytic system.



Scheme S4.1 Representative Cases Highlighting Substrate Limitations

5. Control experiments for the mechanistic investigation

Initially, we reacted compound **1a** (0.5 mmol) with an equal amount of catalyst **C5** in toluene at 80 °C for 24 h under nitrogen atmosphere. Under vacuum, the solution after the reaction was drained to obtain a yellow solid, and the solid obtained was tested by NMR. The results indicated that the ¹H NMR spectral analysis of the reaction between **1a** and **C5** showed no significant changes compared to the original data (**Scheme S5.1** a).

C5 (0.2 mmol) was reacted with 1.0 equivalent of diphenylphosphine oxide in deuterated chloroform (CDCl₃) at 60 °C under a nitrogen atmosphere for 24 hours. After completion of the reaction, the mixture was subjected to ¹H NMR analysis. As shown in **Figure S5.1** b, a new signal appeared at –0.95 ppm in the ¹H NMR spectrum, whereas the corresponding resonance for the starting material **C5** was observed at – 1.23 ppm. The newly emerged signal at –0.95 ppm is tentatively attributed to the Al– Me proton in intermediate **A**. In addition, a distinct new peak was detected at 0.13 ppm, which is consistent with the chemical shift of methane. This observation supports the mechanistic proposal that the formation of intermediate **A** from **C5** and diphenylphosphine oxide is accompanied by the release of one equivalent of methane.



Scheme S5.1 Control experiments



Figure S5.1 ¹H NMR spectrum of a mixture of **C5** and diphenylphosphine oxide: a) before reaction of **C5** with diphenylphosphine oxide; b) after reaction of **C5** with diphenylphosphine oxide.

Finally, we conducted a ³¹P NMR test, which revealed a distinct single peak at 23.01 ppm (Figure S5.2). This result is consistent with similar observations reported in the literature⁶ for Al-O-P, which is typically found around 24.26 ppm.



Figure S5.2 ³¹P NMR spectrum of a mixture after reaction of **C5** with diphenylphosphine oxide

In addition, we performed liquid-phase mass spectrometric (LC-MS) analysis on the reaction mixture obtained from the treatment of **C5** with diphenylphosphine oxide (**2a**). Although partial decomposition occurred during the measurement, a molecular ion corresponding to the proposed structure of intermediate A was still clearly observed. The data are as follows:

MS (ESI-TOF): *m*/*z* [M+H]⁺ calcd for C₃₉H₄₆AlN₂OPH⁺: 617.3241; found: 617.3233.

This result complements the NMR data presented in the main text and strongly supports the in situ formation of intermediate A in the reaction system.

6. References

J. D. Nobbs, D. W. P. Tay, Y. H. Yeap, Y. L. Tiong, S. Ye, S. Aitipamula, C. Wang, C. B. Cheong and M. van Meurs, *Dalton Trans.*, 2023, **52**, 17954-17965.
C. Tan, X. Liu, H. Jia, X. Zhao, J. Chen, Z. Wang and J. Tan, *Chem. Eur. J.*, 2020, **26**, 881-887.

3. G. M. Sheldrick, Acta Cryst. C., 2015, 71, 3-8.

- 4. G. M. Sheldrick, Acta Crystallogr. A Found. Adv., 2008, 64, 112-122.
- 5. G. M. Sheldrick, Acta Crystallogr. A Found. Adv., 2015, 71, 3-8.

6. P. Hao, Z. Yang, X. Ma, X. Wang, Z. Liu, H. W. Roesky, K. Sun, J. Li and M. Zhong, *Dalton Trans.*, 2012, **41**, 13520-13524.